Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s share price reached a new 52-week high on Thursday . The company traded as high as $16.98 and last traded at $16.61, with a volume of 512,813 shares changing hands. The stock had previously closed at $16.22.

Several equities analysts recently commented on LXRX shares. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $16.00 price target on shares of Lexicon Pharmaceuticals in a research report on Thursday, May 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, May 4th. Cowen and Company reaffirmed a “market perform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Lexicon Pharmaceuticals in a research report on Friday, May 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $18.50.

The firm’s market capitalization is $1.69 billion. The stock has a 50 day moving average of $14.60 and a 200-day moving average of $12.51.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.04. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $11.11 million. During the same period last year, the business posted ($0.04) EPS. The company’s quarterly revenue was up 594.4% on a year-over-year basis. Analysts predict that Lexicon Pharmaceuticals Inc. will post ($1.55) EPS for the current year.

In other news, VP James F. Tessmer sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $78,000.00. Following the completion of the transaction, the vice president now owns 21,946 shares in the company, valued at approximately $285,298. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Several hedge funds and institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System boosted its position in shares of Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,372 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 6,390 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock valued at $1,862,000 after buying an additional 77,446 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 125,083 shares during the last quarter.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.